Related Experiment Video

Updated: May 10, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

The path to an RSV vaccine

Christine A Shaw1, Max Ciarlet, Brian W Cooper

  • 1Novartis Vaccines and Diagnostics, Inc., 350 Massachusetts Avenue, Cambridge, MA 02139, United States.

Current Opinion in Virology
|June 4, 2013
PubMed

Insights

Developing a respiratory syncytial virus (RSV) vaccine for infants remains a critical challenge. Overcoming hurdles like disease enhancement and unreliable animal models is key to creating a safe and effective infant RSV vaccine.

Area of Science:

  • Vaccinology
  • Virology
  • Pediatric Infectious Diseases

Background:

  • Respiratory syncytial virus (RSV) represents a significant unmet need for infant vaccines globally.
  • Despite over 40 years of research, a licensed human RSV vaccine is still unavailable.
  • Severe RSV disease peaks in infants aged 2-3 months, highlighting the urgency for effective immunization strategies.

Purpose of the Study:

  • To review the major challenges hindering the development of a safe and effective RSV vaccine for infants.
  • To explore potential strategies and novel approaches to overcome existing obstacles in RSV vaccine research.
  • To identify promising avenues for future RSV vaccine development, focusing on infant protection.

Main Methods:

  • Review of historical RSV vaccine development efforts and associated challenges.
  • Analysis of the immunological and virological factors complicating RSV vaccine design.
  • Exploration of emerging technologies and immunization platforms for RSV vaccine candidates.

Main Results:

  • Key challenges include the timing of severe disease in infants, antigen instability, vaccine-mediated disease enhancement, and inadequate animal models.
  • Past vaccine trials have faced significant hurdles, including safety concerns and lack of efficacy.
  • No RSV vaccine has yet been successfully licensed for human use, particularly for infants.

Conclusions:

  • Maternal immunization offers a potential strategy to protect young infants.
  • Structure-based antigen engineering and novel immunization platforms are promising for future RSV vaccines.
  • Development of better animal models is crucial for accurately assessing RSV vaccine safety and efficacy.

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...